Business / Finance

RSS

Drug co. executive gives pharma a sunny forecast

Severin Schwan thinks the skeptics are wrong. Those who shun the pharmaceutical sector for its lack of prospects don't understand the potential created by a rapidly growing understanding of genetics and molecular biology, and the new drugs that will follow. ... the chief executive of Roche Holding AG, the world's seventh-largest drug firm by sales, is an informed optimist.

22 Aug 2011

Nightingale receives ISO 13485:2003 certification for EMR and associated services

Nightingale Informatix Corporation, a developer and provider of web-hosted Electronic Medical Record (EMR) software and associated services, announced today that it has received ISO 13485:2003 certification.

22 Aug 2011

UHC report outlines ways to combat high cost of care through supply chain purchasing process

While health care reform looks at ways to combat the high cost of care, many of the nation's top hospitals have already found ways to eliminate unnecessary costs through the supply chain purchasing process.

20 Aug 2011

SVEFCU approves a merger with McGraw-Hill Federal Credit Union

Following a vote of its membership on August 18, St. Vincent's Employees Federal Credit Union (SVEFCU) has approved a merger with McGraw-Hill Federal Credit Union.

20 Aug 2011

HDS discusses market opportunity linked with carbon sequestration technologies

HDS International Corp., a provider of industrial ocean-based biomass production and other high-value eco-sustainability solutions, today discussed the market opportunity associated with its carbon sequestration technologies.

20 Aug 2011

Duke LifePoint to acquire Person Memorial Hospital

Duke LifePoint Healthcare, a joint venture of Duke University Health System, Inc. and LifePoint Hospitals, and the Person Memorial Hospital (PMH) Board of Trustees today announced that they have signed a definitive agreement for Duke LifePoint to acquire PMH.

20 Aug 2011

Tibet Pharmaceuticals second quarter revenue increases 12% to $8.7 million

Tibet Pharmaceuticals, Inc., an emerging specialty pharmaceutical company engaged in the development, manufacturing and marketing of traditional Tibetan medicine in China, today announced the availability of the transcript for its second quarter 2011 earnings conference call, held on August 16th.

20 Aug 2011

Cannabis Science enters distribution agreement with PVM for marijuana dispensing machines

Cannabis Science, Inc., a pioneering US biotech company developing pharmaceutical cannabis products, is pleased to announce that Cannabis Science has entered into an exclusive distribution Agreement with Prescription Vending Machines Inc. ("PVM") and contracted with PVM's principal Vincent Mehdizadeh to provide industry specific consulting and advisory services to Cannabis Science.

19 Aug 2011

DiaGenic reports operating revenue of NOK 1,151 thousand for second quarter 2011

DiaGenic: Important milestones achieved. DiaGenic's collaboration with Pfizer is the first collaboration between a diagnostics company and the market leader for Alzheimer's therapeutics that aims to identify blood based diagnostic tools that can detect early Alzheimer's disease, before the disease is clinically overt, or accessible to other either more invasive and costly or less precise diagnostic exploration.

19 Aug 2011

Furiex enters loan agreement with MidCap Financial, Silicon Valley Bank

Furiex Pharmaceuticals, Inc. announced today it has entered into a loan agreement with MidCap Financial and Silicon Valley Bank to provide up to $15.0 million in capital through a secured term loan. Furiex intends to use the proceeds to support research and development for its clinical stage compounds JNJ-Q2, MuDelta and PPD10558.

19 Aug 2011

Atrium Innovations acquires Enzimas

Atrium Innovations Inc., a globally recognized leader in the development, manufacturing, and commercialization of innovative, science-based dietary supplements endorsed by health professionals, today announced the acquisition of Enzimas S.A., a manufacturer of Trypsin and Chymotrypsin enzymes based in Lujan, Argentina.

19 Aug 2011

Medical Connections second quarter revenue decreases 6.8% to $1,779,938

Medical Connections Holdings, Inc. a national provider of healthcare staffing services, announced today its operating results for the second quarter and the first six months of 2011. Revenue for the second quarter of 2011 was $1,779,938, a decrease of 6.8% when compared to the second quarter of 2010.

18 Aug 2011

Cortex second quarter net loss decreases to $356,000

Cortex Pharmaceuticals, Inc. reported a net loss of approximately $356,000, or $0.00 per share, for the quarter ended June 30, 2011, compared with a net loss of approximately $2,454,000, or $0.04 per share, for the corresponding prior year period, with the difference reflecting revenues in the current year period from the Company's option agreement with Servier, France's largest privately held pharmaceutical company.

18 Aug 2011

How the Medco-Express Scripts merger could impact consumer pocketbooks

You probably haven't heard of either Express Scripts or Medco Health Services, but their plans to merge in a $29 billion deal, announced last month, may have an impact on your pocketbook.

18 Aug 2011

Henry Schein authorizes repurchase of $200M shares of common stock

Henry Schein, Inc., the largest provider of health care products and services to office-based practitioners, today announced that its Board of Directors has authorized the repurchase of up to $200 million of shares of the Company's common stock.

18 Aug 2011

Kensey Nash fourth quarter total revenues decrease 14% to $18.7 million

Kensey Nash Corporation, a medical device company primarily focused on regenerative medicine for a wide range of medical procedures, today reported the results for its fourth quarter and fiscal year ended June 30, 2011.

18 Aug 2011

Celgene expands share repurchase program

Celgene Corporation announced the Company's Board of Directors has authorized the repurchase of up to an additional $2 billion of the Company's common stock.

18 Aug 2011

Neoprobe sells gamma detection device business to Devicor

Neoprobe Corporation, a diversified developer of innovative oncology surgical and diagnostic products, announced today that it completed the previously announced sale of its neoprobe GDS line of gamma detection device systems to Devicor Medical Products, Inc. for $30 million in upfront consideration, plus up to an additional $20 million in royalties based on Devicor's achievement of certain revenue milestones.

18 Aug 2011

Paladin to acquire Labopharm

Paladin Labs Inc. and Labopharm Inc. announced today that they have entered into a definitive agreement pursuant to which Paladin will acquire all of the issued and outstanding common shares of Labopharm at a price of $0.2857 per share in cash, which represents a premium of 57.4% over the volume-weighted average price of Labopharm's shares of $0.1815 for the 30 trading days prior to this announcement.

18 Aug 2011